ASA Silverarc Strategy

Investment Opportunity

The strategy seeks to deliver attractive returns through exposure to equities of companies within the healthcare sector, with an emphasis on those involved in the development of new therapeutics, including biotechnology firms. It pursues this objective by investing in an equity long-short hedge fund, the SilverArc Capital Alpha Fund.

Key Information

Fiduciary Structure: Delaware Multi-Series Limited Partnership

Investment Manager: ASA Asset Management LLC

Fund Launch: April 2026

Benchmark: None

Base Currency: USD

NAV Calculation Frequency: Monthly

Liquidity Terms:

Subscription: Monthly
Redemption: Quarterly
Notice: 7 days for subscription and 65 days for redemption requests
Fund Level Gate: 5%
Lock Up: 12 Months

Strategy Highlights

The strategy employs a low-net long/short equity approach focused on biotechnology, investing in equities and equity derivatives based on deep fundamental research.

A specialized team of nine professionals combines scientific expertise with an extensive network of clinicians, researchers, and industry executives to support idea generation, underwriting, and disciplined risk management.

Portfolio Role

We believe biotechnology represents one of the most compelling opportunity sets in global equities, driven by accelerating drug innovation, expanding clinical pipelines, and sustained capital allocation toward life sciences. This environment creates opportunities to capture asymmetric upside from breakthrough developments while actively managing downside risk through a disciplined long/short investment framework.